Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Afinitor Significantly Increased PFS in Women with Advanced Breast Cancer: Novartis
October 3, 2011
- Asahi Kasei Pharma, tella Announce Joint R&D Agreement for Cell Processing Equipment
October 3, 2011
- Maruho Establishes US Subsidiary
October 3, 2011
- Ono: Corebeta for Inj. 12.5 mg for Improving Image Quality in Coronary CT Angiography
October 3, 2011
- Novartis Pharma: COPD Treatment Onbrez Inhalation Capsules
October 3, 2011
- Nesina Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
October 3, 2011
- Toyobo Biologics Partners with Catalent to Strengthen Contract Manufacturing Business
October 3, 2011
- MSD, Hisamitsu to Terminate Copromotion of Fosamac in February 2012
October 3, 2011
- Barclays Raises MTPC’s Target Share Price on Telavic Survey
October 3, 2011
- Support of Gov’t, Industry Essential for Development of RNA-based Drugs: PMRJ Seminar
October 3, 2011
- SGLT2 Inhibitor Ipragliflozin Significantly Reduced HbA1c in PIII Study: Astellas
October 3, 2011
- Weight Gain with Lantus Lowest in Patients with HbA1c Below 8%: Sanofi
October 3, 2011
- NBI, Eli Lilly Japan: DPP-4 Inhibitor Trazenta Tablets 5 mg for Type 2 Diabetes
October 3, 2011
- Taiho: CTCL Treatment Zolinza Capsules 100 mg
October 3, 2011
- Pfizer Starts New Online Promotion with MedPeer
September 30, 2011
- MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
- Takeda Files NDA for Hyperlipidemia Treatment TAK-085 in Japan
September 30, 2011
- Imatinib Significantly Improves Walking Distance in Patients with PAH: Novartis
September 30, 2011
- Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
- Santen to Acquire French Drugmaker, Strengthen R&D
September 29, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…